LABORIE completed its acquisition of BUCK Elektromedizin GmbH and BUCKmeditec GmbH & Co. BUCK, headquartered in Bad Rappenaeau, Germany, develops and distributes innovative and advanced Biofeedback and electrical stimulation equipment, accessories and consumables for pelvic floor dysfunction in the treatment of Urinary and Fecal incontinence.
“Both LABORIE and BUCK have a shared commitment to helping healthcare professionals deliver better products and services, and to make life more rewarding and dignified for those who use our products,” stated Brian Ellacott, LABORIE President and CEO. “By combining existing product lines with BUCK’s extensive customer base, we can provide a greater breadth of innovative products and services to enable German urologists to deliver better care to their patients.”
LABORIE’s acquisition of BUCK further extends its market leadership in Pelvic Muscle Rehabilitation. The acquisition also expands LABORIE’s presence in the German market by adding 15 in-country sales representatives that will market the full range of both LABORIE and BUCK products.
BUCK managing director Franz Dettling said, “We are excited to partner with a global leader in urology who will help us expand the breadth of our offering to German urologists as well as help provide access to our unique pelvic therapy offerings around the world.”
LABORIE (www.laborie.com), headquartered in Toronto, Canada, is a leading global developer, manufacturer and marketer of innovative medical technology and consumables used for the diagnosis and treatment of Urinary and Fecal Incontinence, as well as other pelvic floor disorders in the Urology, Gynecology, and Colorectal fields.
LABORIE Medical Technologies, a leading global developer and manufacturer of medical diagnostics and devices in the pelvic health and gastroenterology market, today announces the execution of a definitive agreement to acquire Clinical Innovations for an enterprise value of $525 million.
LABORIE Medical Technologies (“LABORIE”) and Cogentix Medical, Inc. (NASDAQ: CGNT) (“Cogentix”) today announced the completion of the acquisition by LABORIE of Cogentix through LABORIE’S affiliate Camden Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of LM US Parent, Inc. (“Parent”).
LABORIE Medical Technologies (“LABORIE”) announced the successful completion of the tender offer by its affiliate Camden Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of LM US Parent, Inc. (“Parent”) to purchase all outstanding shares of common stock of Cogentix Medical, Inc. (NASDAQ: CGNT) (“Cogentix”)